AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer

Completed · Phase 2

Conditions studied: Pancreatic Neoplasms

In brief

This is a Phase 2 study being conducted at multiple centers in the United States, Europe and Canada. Patients having pancreatic cancer that is locally advanced or that has spread to other parts of the body (i.e., metastatic) are eligible to participate. Patients must have not had any prior systemic treatment for advanced disease. The purpose of the study is to test whether the angiogenesis inhibitor Axitinib \[AG-013736\] in combination with gemcitabine is an effective treatment for advanced pancreatic cancer vs. gemcitabine alone by overall survival.

Key facts

Study ID

NCT00219557

Run by

Pfizer

People needed

111

Starts

2005-07-05

Expected to finish

2008-03-14

Last updated by the study team

2019-05-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• patients with advanced (localized but surgically unresectable or metastatic) histologically/cytologically proven epithelial cancer of the exocrine pancreas
• no prior therapy for metastatic disease

You may not qualify if…

• patients with locally advanced disease who are candidates for radiation therapy.
• uncontrolled brain metastases (a controlled brain metastasis must be previously treated, asymptomatic, and without growth for 4 months)

Where it is running

• East Bay Medical Oncology/Hematology Medical Associates Inc. — Antioch, California, United States
• Alta Bates Comprehensive Cancer Center — Berkeley, California, United States
• Bay Area Cancer Research Group — Concord, California, United States
• East Bay Medical Oncology/Hematology Medical Associates, Inc. — Concord, California, United States
• Hematology Oncology, P.C. — Stamford, Connecticut, United States
• Jackson Memorial Hospital & Clinics — Miami, Florida, United States
• University of Miami Hospital & clinics — Miami, Florida, United States
• H Lee Moffitt Cancer Center & Research Institute — Tampa, Florida, United States
• Maine Center for Cancer Medicine and Blood Disorders — Biddeford, Maine, United States
• Maine Center for Cancer Medicine and Blood Disorders — Brunswick, Maine, United States
• Maine Center for Cancer Medicine and Blood Disorders — Scarborough, Maine, United States
• Arch Medical Services, Inc. d/b/a The Center for Cancer Care and Research — St Louis, Missouri, United States
• Arch Medical Services, Inc. d/b/a The Center for Cancer Care and Research — Washington, Missouri, United States
• Southeast Nebraska Cancer Center, Southeast Nebraska Hematology and Oncology Consultants, P.C. — Lincoln, Nebraska, United States
• Piedmont Hematology Oncology Association — Winston-Salem, North Carolina, United States
• Piedmont Hematology Oncology Associates — Winston-Salem, North Carolina, United States
• University of Wisconsin Hospital and Clinics — Madison, Wisconsin, United States
• Universitair Ziekenhuis Gent/Dienst Gastroenterologie — Ghent, Belgium
• Cross Cancer Institute — Edmonton, Alberta, Canada
• Cancer Care Manitoba — Winnipeg, Manitoba, Canada
• CancerCare Manitoba — Winnipeg, Manitoba, Canada
• Sault Area Hospital — Sault Ste. Marie, Ontario, Canada
• Princess Margaret Hospital — Toronto, Ontario, Canada
• CHUM, Hopital Saint-Luc — Montreal, Quebec, Canada
• Service Oncologie Medicale — Saint-Herblain, Saint Herblain Cedex, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.